Skip to main content

Correction to: Novel sulphamoylated 2-methoxy estradiol derivatives inhibit breast cancer migration by disrupting microtubule turnover and organization

The Original Article was published on 03 January 2019

Correction to: Cancer Cell Int (2019) 19:1 https://doi.org/10.1186/s12935-018-0719-4

Following publication of the original article [1], the authors notified us that the graph presented in Figure 3a is the same as Figure 2a in the published manuscript. Figure 3 below represents the true migration values achieved for cells blocked in interphase and treated with the different compounds.

Fig. 3
figure 3

Migration of interphase arrested cells is inhibited by ESE-15-one and ESE-one exposure. a MDA-MB-231 cells were first blocked in G1/S by exposure to thymidine before cell free zones were generated and cells were exposed to 0.2% DMSO, 0.5 μM ESE-15-one or 0.5 μM ESE-one. Cell migration into the cell-free zone was quantified after 18 h. The graph represents the average of at least three repeats with error bars representing SEM. *P < 0.001 in t-test comparison with DMSO-treated cells. b Light microscopy images of cell migration assays showing interphase cells at time 0 h and after 18 h treated with DMSO, ESE-15-one or ESE-one. Scale bar is 400 μm

Specifically, blocked cells treated with DMSO closed 35% of the wound while ESE-15-one reduced that to 23% and ESE one reduced this to 13%. T tests show statistical significance.

Reference

  1. van Vuuren RJ, Botes M, Jurgens T, Joubert AM, van den Bout I. Novel sulphamoylated 2-methoxy estradiol derivatives inhibit breast cancer migration by disrupting microtubule turnover and organization. Cancer Cell Int. 2019;19:1. https://doi.org/10.1186/s12935-018-0719-4.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Iman van den Bout.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

van Vuuren, R.J., Botes, M., Jurgens, T. et al. Correction to: Novel sulphamoylated 2-methoxy estradiol derivatives inhibit breast cancer migration by disrupting microtubule turnover and organization. Cancer Cell Int 20, 308 (2020). https://doi.org/10.1186/s12935-020-01408-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s12935-020-01408-3